45 results on '"Kasymjanova G"'
Search Results
2. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer
3. A comparison of the effects of medical Qigong and standard exercise therapy on symptoms and quality of life in patients with advanced cancer
4. EP06.01-001 The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review
5. EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer
6. EP11.03-001 Loss of SUSD2 Expression in Lung Adenocarcinoma Correlates with Solid Pattern, Higher Histological Grading and Higher Ki-67 Cycling Index
7. P3.06D.08 ctDNA-NGS Assay (Liquid Biopsy) for Non-Small Cell Lung Cancer: Utility of Plasma Cell-Free DNA and Tissue NGS in Detecting Genetic Mutations
8. Validation of Known Radiomics Biomarkers for Post-Treatment Local Response for SBRT-Treated NSCLC, Using Machine Learning
9. 1798P Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
10. P31.01 Impact of COVID-19 on Lung Cancer Diagnosis and Treatment: A Retrospective Chart Review
11. P24.11 Cell-Free Tumor DNA (ctDNA) Utility in Detection and Monitoring EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
12. 1425P Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
13. Understanding Clinical Practice and Survival Outcomes in Patients with Unresectable Stage III Non-Small-Cell Lung Cancer in a Single Centre in Quebec
14. P1.01-99 EGFR-Wild Type Patients Responding to TKI: Revisiting Pathology with Newer Technology
15. Erratum to “The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma” [Lung Cancer 132 (June) (2019) 36–38]
16. P1.01-52 Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
17. MA16.09 Clinical Practice and Outcomes in Patients with Stage III Unresectable Non-Small-Cell Lung Canceran Academic Centre, Canada
18. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma
19. Detection of T790M Mutation in Blood Versus Tumor Tissue Biopsy
20. Does the Presence of Emphysema Increase the Risk of Radiation Pneumonitis in Lung Cancer Patients?
21. P1.04-16 Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC with High PD-L1 Expression Tested on Cytology Versus Biopsy Samples
22. P2.09-07 Does Metastatic Site Matter for PD-L1 Testing in Stage IV NSCLC?
23. MA09.09 EBUS-TBNA in Assessing PD-L1 Expression in NSCLC
24. P2.01-04 Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center
25. MA21.09 Differential Gene Expression in Tumor and Normal Tissue Reveals New Insights in the Biology of Non-Small Cell Lung Carcinoma.
26. PUB079 Detection of the EGFR P.(T790M) Mutation by Different Methods: A Small Comparison Case Study
27. P2.02-040 Cytology Cell Block Is Suitable for Immunohistochemical Testing for PD-L1 in Lung Cancer
28. P3.02-055 Detecting ALK, ROS1 and RET Gene Translocations in Non-Small Cell Lung Cancer (NSCLC) with the NanoString Platform
29. Lung Cancer Care Trajectory at a Canadian Centre: An Evaluation of How Wait Times Affect Clinical Outcomes
30. An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre
31. Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre
32. Treatment patterns and outcomes in KRAS G12C -positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
33. Real-World Evidence of the Impact of the COVID-19 Pandemic on Lung Cancer Survival: Canadian Perspective.
34. Prognostic factors for the development of acneiform eruptions in patients on epidermal growth factor receptor inhibitors.
35. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center.
36. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
37. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
38. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review.
39. The use of a standardized Chinese herbal formula in patients with advanced lung cancer: a feasibility study.
40. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
41. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype.
42. Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data.
43. Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
44. Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation.
45. Phenotypic heterogeneity of potentially curable non-small-cell lung cancer: cohort study with cluster analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.